Pmv Financial Statements From 2010 to 2026

PMVP Stock  USD 1.22  0.01  0.81%   
Analyzing historical trends in various income statement and balance sheet accounts from Pmv Pharmaceuticals' financial statements helps investors evaluate the company's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Pmv Pharmaceuticals' valuation are summarized below:
Market Capitalization
65.5 M
Earnings Share
(1.59)
There are currently one hundred twenty trending fundamental ratios for Pmv Pharmaceuticals that can be evaluated and compared over time across competitors. Investors and active traders are advised to check out Pmv Pharmaceuticals' recent fundamental performance against the performance between 2010 and 2026 to make sure the trends are evolving in the right direction. As of 01/06/2026, Market Cap is likely to drop to about 433.4 M. In addition to that, Enterprise Value is likely to drop to about 330.3 M
Check Pmv Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Pmv Pharmaceuticals' main balance sheet or income statement drivers, such as Net Interest Income of 12.9 M, Interest Income of 12.9 M or Depreciation And Amortization of 1.4 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 0.42. Pmv financial statements analysis is a perfect complement when working with Pmv Pharmaceuticals Valuation or Volatility modules.
  
Build AI portfolio with Pmv Stock
Check out the analysis of Pmv Pharmaceuticals Correlation against competitors.
To learn how to invest in Pmv Stock, please use our How to Invest in Pmv Pharmaceuticals guide.

Pmv Pharmaceuticals Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets247.9 M220 M150.2 M
Slightly volatile
Short and Long Term Debt TotalM1.1 M69.8 M
Slightly volatile
Other Current Liabilities6.5 M8.6 M3.9 M
Slightly volatile
Total Current Liabilities10.2 M16.5 M6.5 M
Slightly volatile
Other Liabilities51.7 K58.6 K47.3 K
Slightly volatile
Property Plant And Equipment Net1.7 M1.8 MM
Slightly volatile
Accounts Payable7.9 M7.6 M2.7 M
Slightly volatile
Cash34.9 M36.8 M67 M
Pretty Stable
Non Current Assets Total18.4 M18 M9.6 M
Slightly volatile
Non Currrent Assets Other245.5 K270.2 K216.8 K
Slightly volatile
Other Assets0.860.9161.5 K
Slightly volatile
Cash And Short Term Investments225.6 M194.9 M138.3 M
Slightly volatile
Common Stock Shares Outstanding44.2 M59.3 M24 M
Slightly volatile
Liabilities And Stockholders Equity247.9 M220 M150.2 M
Slightly volatile
Non Current Liabilities Total716.5 K754.2 K69.1 M
Slightly volatile
Other Current Assets3.9 M7.1 M2.3 M
Slightly volatile
Other Stockholder Equity396.3 M626.4 M210.4 M
Slightly volatile
Total Liabilities13 M13.7 M75.4 M
Slightly volatile
Property Plant And Equipment Gross3.3 M3.5 M4.5 M
Slightly volatile
Total Current Assets229.5 M202 M140.6 M
Slightly volatile
Non Current Liabilities Other16.2 M15.5 M5.5 M
Slightly volatile
Net Working Capital219.3 M185.5 M134.1 M
Slightly volatile
Property Plant Equipment13.2 M12.6 M4.8 M
Slightly volatile
Capital Surpluse525.4 M560.6 M481.4 M
Slightly volatile
Short Term Debt587.1 K404.8 K444.7 K
Slightly volatile
Current Deferred Revenue73.6 K82.8 K90.4 K
Slightly volatile

Pmv Pharmaceuticals Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Net Interest Income12.9 M12.3 M3.7 M
Slightly volatile
Interest Income12.9 M12.3 M3.7 M
Slightly volatile
Depreciation And Amortization1.4 M1.3 M556.9 K
Slightly volatile
Selling General Administrative18.8 M31 M12.4 M
Slightly volatile
Other Operating Expenses59.9 M98.3 M40.6 M
Slightly volatile
Research Development40.7 M66 M28 M
Slightly volatile
Cost Of Revenue844.8 K1.3 M602.4 K
Slightly volatile
Total Operating Expenses59.5 M96.9 M40.4 M
Slightly volatile
Reconciled Depreciation1.4 M1.3 M540.2 K
Slightly volatile
Total Other Income Expense Net12.8 M12.2 M3.8 M
Slightly volatile
Non Operating Income Net Other4.5 M4.3 M1.5 M
Slightly volatile
Selling And Marketing Expenses19.4 M21.8 M23.8 M
Slightly volatile

Pmv Pharmaceuticals Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation6.4 M10.2 M3.9 M
Slightly volatile
Begin Period Cash Flow42.1 M44.3 M63.9 M
Slightly volatile
Other Cashflows From Financing Activities267.6 K281.7 K19.5 M
Slightly volatile
Depreciation844.8 K1.3 M602.4 K
Slightly volatile
Capital Expenditures715.6 K753.2 K984.9 K
Slightly volatile
Total Cash From Financing Activities267.6 K281.7 K55.9 M
Pretty Stable
End Period Cash Flow34.9 M36.8 M67.1 M
Pretty Stable
Change To Netincome12.2 M11.6 M4.5 M
Slightly volatile
Sale Purchase Of Stock819.1 K862.2 K190 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Capex To Depreciation0.490.522.6394
Pretty Stable
Payables Turnover0.210.160.2833
Slightly volatile
Cash Per Share3.593.7813.0255
Slightly volatile
Days Payables Outstanding1.8 K2.4 K1.4 K
Slightly volatile
Income Quality0.951.00.8774
Slightly volatile
Current Ratio13.3514.0624.8279
Slightly volatile
Capex Per Share0.01390.01460.0951
Slightly volatile
Interest Debt Per Share0.02520.026519.0714
Slightly volatile
Debt To Assets0.00680.00721.0023
Slightly volatile
Days Of Payables Outstanding1.8 K2.4 K1.4 K
Slightly volatile
Ebt Per Ebit1.021.010.9412
Slightly volatile
Total Debt To Capitalization0.00730.00771.042
Slightly volatile
Quick Ratio13.3514.0624.8279
Slightly volatile
Net Income Per E B T1.070.90.9857
Slightly volatile
Cash Ratio3.113.2713.2839
Pretty Stable
Free Cash Flow Operating Cash Flow Ratio0.820.911.0113
Slightly volatile
Debt Ratio0.00680.00721.0023
Slightly volatile

Pmv Pharmaceuticals Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap433.4 M456.2 M1.3 B
Slightly volatile
Enterprise Value330.3 M347.7 M1.3 B
Slightly volatile

Pmv Fundamental Market Drivers

Pmv Upcoming Events

6th of March 2024
Upcoming Quarterly Report
View
8th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
6th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Pmv Pharmaceuticals Financial Statements

Pmv Pharmaceuticals shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Pmv Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. The changes in Pmv Pharmaceuticals' assets and liabilities, for example, are also reflected in the revenues and expenses on on Pmv Pharmaceuticals' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue82.8 K73.6 K
Cost Of Revenue1.3 M844.8 K

Pair Trading with Pmv Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Pmv Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Pmv Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Moving against Pmv Stock

  0.81FTV Fortive CorpPairCorr
  0.69JPM JPMorgan Chase Earnings Call This WeekPairCorr
  0.69MRK Merck CompanyPairCorr
  0.66CAT CaterpillarPairCorr
  0.66TRV The Travelers CompaniesPairCorr
The ability to find closely correlated positions to Pmv Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Pmv Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Pmv Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Pmv Pharmaceuticals to buy it.
The correlation of Pmv Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Pmv Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Pmv Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Pmv Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Additional Tools for Pmv Stock Analysis

When running Pmv Pharmaceuticals' price analysis, check to measure Pmv Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pmv Pharmaceuticals is operating at the current time. Most of Pmv Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Pmv Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pmv Pharmaceuticals' price. Additionally, you may evaluate how the addition of Pmv Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.